Sampad Roy, National Hospital Sales Manager at Unilever, shared a post on LinkedIn:
“BREAKTHROUGH in the fight against metastatic triple-negative breast cancer (mTNBC).
Gilead Sciences just dropped major Phase 3 data — and it could redefine how we treat one of the most aggressive forms of breast cancer.
Here’s what you need to know:
- The combo of Trodelvy and Keytruda significantly improved progression-free survival (PFS) over the current standard (Keytruda + chemo).
- First time an antibody-drug conjugate + immunotherapy combo has shown this level of promise in early-line metastatic breast cancer.
- Safety profile? Consistent with known data — no new red flags..
- Early signs of improved overall survival (OS) are emerging — full data still maturing.
- Study included 443 patients with PD-L1+ mTNBC (CPS ≥10) — one of the toughest cancer subtypes to treat.
Why this matters:
Triple-negative breast cancer (TNBC) lacks traditional receptors (estrogen, progesterone, HER2), limiting treatment options. PD-L1+ TNBC is even more aggressive.
This study opens the door to a new standard of care — with a targeted antibody-drug conjugate delivering chemo directly to cancer cells, paired with the immune-boosting power of Keytruda.
A win for science.
A win for patients.
And a potential paradigm shift in breast cancer treatment.
What do you think — are ADC + IO combinations the future of oncology?
Let’s discuss.”
